A recent study shows that ivermectin, a common head lice drug, may be a suitable treatment for COVID-19. Per the New York Post, during the study, there was an 80% reduction in deaths.
The outlet states, “Just 8 out of 573 patients who received ivermectin passed away, compared to the 44 individuals out of 510 who died after being given a placebo.”
Ivermectin costs between $17 and $43, and in the study done in April, it removed all viral RNA within 48 hours of a single dose.
Although some are hopeful that this drug will work, others are skeptical, and feel that the buzz surrounding it is similar to the talk about hydroxychloroquine and tocilizumab.
University of Sydney professor Andrew McLachlan points out, “Many of the current studies have low numbers of participants, weak study designs, and inconsistent (and relatively low) ivermectin dosing regimes, with ivermectin frequently given in combination with other drugs.”